Study guide

11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

Certified Addictions Registered Nurse - Advanced Practice CARN-AP

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice

About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care

2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance

1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene

3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone

2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)

4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications

5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds

7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions

7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice

9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning

8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines

9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP

12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing

11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine

14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education

15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition

14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol

16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support

17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations

16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy

17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM

20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)

20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation

22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction

11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

Key Takeaways Explain This Topic AI

Prescription Drug Monitoring Programs (PDMP) track controlled substance dispensations to identify high-risk co-prescribing (≥50-90 MME/day, opioid-benzodiazepine overlap) and multi-prescriber patterns.

PDMP discrepancies must be approached with curiosity-based, non-judgmental clinical communication—never with punitive discharge or treatment abandonment.

Urine drug testing (UDT) immunoassays are rapid qualitative screens prone to false positives (e.g., bupropion for amphetamine) and blind spots (missing synthetic opioids like fentanyl, methadone, and buprenorphine).

Confirmatory testing (GC-MS / LC-MS/MS) provides definitive quantitative identification: 6-monoacetylmorphine (6-MAM) confirms heroin use, while parent buprenorphine without norbuprenorphine proves pill spiking.

Clinical governance demands using UDT as a diagnostic and therapeutic safety tool to assess adherence and guide harm reduction, never as an interrogation or punitive weapon.

Last updated: September 2026

11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

Core Clinical Competency: The Advanced Practice Registered Nurse (APRN) must synthesize electronic Prescription Drug Monitoring Program (PDMP) surveillance data and advanced toxicological testing methodologies (point-of-care immunoassay vs. definitive mass spectrometry) to monitor patient safety, detect metabolic divergence, identify specimen tampering, and deliver ethical, non-punitive addiction care.

1. Prescription Drug Monitoring Programs (PDMP): Clinical Governance & Surveillance

Prescription Drug Monitoring Programs (PDMPs) are state-administered electronic databases that collect, monitor, and analyze designated controlled substance (Schedules II–V) dispensations submitted by outpatient retail and mail-order pharmacies. Most state systems are interconnected through national data-sharing hubs (e.g., PMP InterConnect), enabling prescribers to review controlled substance histories across state lines.

Clinical Governance & Mandates for PDMP Query

Best practice guidelines established by the CDC, ASAM, and state licensing boards dictate specific clinical checkpoints for mandatory PDMP review:

Initial Evaluation: Prior to initiating any controlled substance (opioids, stimulants, benzodiazepines, buprenorphine).

Periodic Surveillance: At least quarterly (every 90 days) during chronic therapy, or before every early refill request, unexplained dose escalation, or signs of intoxication/aberrant behavior.

Transitions of Care: Upon hospital discharge, emergency department evaluation, or transfer between clinics.

High-Risk PDMP Indicators ("Red Flags") PDMP Risk Stratification & Clinical Action:

  • [PDMP Query Performed]
  • │
  • ┌────────┴────────────────────────┬────────────────────────┐
  • ▼ ▼ ▼
  • [High Cumulative MME] [Dangerous Combinations] [Multi-Provider / Pharmacy]
  • ≥50 MME/day: Caution • Opioids + Benzodiazepines • Multiple prescribers/pharmacies
  • ≥90 MME/day: High Risk • Opioids + Sedatives/Carisoprodol • Cash fills despite insurance
  • │ │ │
  • └─────────────────────────────────┼────────────────────────┘
  • ▼
  • [Clinical Action Required]
  • Co-prescribe Naloxone immediately
  • Non-punitive exploratory dialogue
  • Evaluate for unaddressed pain or OUD
  • Offer MOUD (buprenorphine/methadone)

High Cumulative Morphine Milligram Equivalents (MME):

≥50 MME/day: Threshold for heightened caution; risk of fatal overdose doubles compared to <20 MME/day. Re-evaluate pain etiology and increase monitoring frequency.

≥90 MME/day: Substantial overdose mortality risk. Federal guidelines advise against titrating beyond 90 MME/day without explicit clinical justification, pain specialist consultation, and mandatory co-prescribing of take-home naloxone .

Dangerous Pharmacological Combinations:

Concurrent Opioids and Benzodiazepines: Combined ingestion accounts for nearly 30% of prescription opioid overdose deaths. Synergistic GABAA and mu-opioid receptor stimulation causes profound, uncoupled hypoventilation.

Opioids + Sedatives/Hypnotics or Muscle Relaxants (Carisoprodol/Soma): The classic 'Holy Trinity' (opioid + benzodiazepine + carisoprodol) carries severe abuse and fatal toxicity liability.

Multi-Prescriber & Multi-Pharmacy Dispensations ("Doctor Shopping"): Receiving controlled substance prescriptions from multiple unaffiliated prescribers or filling at multiple geographically dispersed pharmacies within rolling 30- to 90-day intervals.

Cash Transactions: Paying out-of-pocket cash for expensive controlled substances despite possessing active commercial or Medicaid/Medicare health insurance coverage.

The Ethical, Non-Punitive Approach to PDMP Discrepancies

When a PDMP report reveals undisclosed controlled substances, overlapping prescriptions, or early fills, the APRN must never engage in punitive discharge, accusatory confrontation, or patient abandonment. Abrupt discharge or unilateral deprescribing violates nursing ethics and dramatically spikes the patient's risk of fatal overdose by forcing them into the unregulated, fentanyl-contaminated illicit street market. Patient Communication Framework for PDMP Discrepancies:

Step 1: Curiosity-Based, Neutral Opening

"I checked the state prescription monitoring database before our appointment today, as I do for all my patients to ensure safety. I noticed a prescription for oxycodone filled two weeks ago from an urgent care clinic. Help me understand what was going on with your health around that time?"

Step 2: Objective Clinical Exploration

Assess for acute physical trauma, unmanaged chronic pain flare, severe withdrawal distress, psychiatric crisis, or escalating substance use disorder.

Step 3: Therapeutic Collaborative Intervention

Coordinate with the external prescriber, provide overdose education, co-prescribe naloxone, adjust buprenorphine dosing to resolve unmanaged cravings, increase clinic contact frequency, and utilize blister packaging.

2. Urine Drug Testing (UDT): Immunoassay vs. Definitive Chromatography

Urine drug testing is a core diagnostic monitoring modality in addiction medicine. However, misinterpreting toxicological findings can lead to erroneous diagnostic conclusions, unjustified treatment terminations, or missed opportunities to identify relapse.

| Feature | Point-of-Care / Rapid Immunoassay (IA) | Gas Chromatography-Mass Spectrometry (GC-MS) / Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) |

| :--- | :--- | :--- | |

| Methodology | Competitive antibody-antigen binding assay using predetermined qualitative threshold cutoffs. | Physical molecular separation via chromatographic column followed by mass-to-charge ( m / z m/z m / z ) spectral fragmentation analysis. |

| Turnaround Time | Immediate (5 to 15 minutes); available in-clinic. | 24 to 72 hours; requires specialized reference laboratory instrumentation. |

| Result Type | Qualitative ONLY (Presumptive Positive or Negative). | Quantitative (reports exact nanogram/milliliter [ng/mL] concentrations of specific molecules). |

| Sensitivity / Specificity | Prone to false positives (antibody cross-reactivity) and false negatives (blind spots). | Gold Standard: Near 100% sensitivity and specificity. Eliminates cross-reactivity. |

| Synthetic Opioid Detection | BLIND SPOT: Fails to detect synthetic opioids (fentanyl, buprenorphine, methadone) unless specialized dedicated assays are ordered. | Detects and quantifies all synthetic opioids, analogues, parent drugs, and specific metabolites. |

| Clinical Utility | Rapid initial triage; guides immediate conversation during appointment. | Confirmatory testing for all unexpected positive or negative screens; forensic validation. |

  • 3. Immunoassay Cross-Reactivity: Common False Positives & Critical Blind Spots
  • Documented Immunoassay Cross-Reactions (False Positives)

Immunoassays rely on antibodies that target specific chemical pharmacophores. Structural mimics frequently bind to the test antibodies, generating false-positive presumptive screens: Common Immunoassay Cross-Reactivities:

  • Presumptive Positive ◄── Cross-Reacting Therapeutic Medication
  • ─────────────────────────────────────────────────────────────────────────────
  • Amphetamines ◄── Bupropion (Wellbutrin), Pseudoephedrine, Labetalol,
  • Ranitidine, Trazodone, Phenylephrine, Vicks VapoInhaler
  • PCP (Phencyclidine) ◄── Dextromethorphan (DXM), Diphenhydramine (Benadryl),
  • Tramadol, Venlafaxine (Effexor)
  • Opiates (Standard) ◄── Fluoroquinolones (Levofloxacin, Ciprofloxacin, Ofloxacin),
  • Rifampin, Poppy seed ingestion (dietary morphine/codeine)
  • Benzodiazepines ◄── Sertraline (Zoloft), Oxaprozin (Daypro)
  • Cannabinoids (THC) ◄── Efavirenz, NSAIDs (historical/rare), Proton Pump Inhibitors
  • Critical Immunoassay Blind Spots (False Negatives)

The standard point-of-care "Opiate" immunoassay cup utilizes antibodies calibrated to detect natural phenanthrene opium alkaloids : Morphine and Codeine (and semi-synthetics such as hydrocodone or hydromorphone at high concentrations).

The Synthetic Opioid Blind Spot: Standard opiate screens DO NOT DETECT synthetic opioids or distinct chemical classes:

  • Fentanyl (synthetic phenylpiperidine)
  • Buprenorphine (semi-synthetic thebaine derivative)
  • Methadone (synthetic diphenylheptane)

Oxycodone / Oxymorphone (frequently missed on standard opiate screens; requires a dedicated oxycodone antibody assay)

Tramadol, Tapentadol, Meperidine

Clinical Implication: A patient maintained on buprenorphine who produces a "Negative Opiate" result on a standard rapid cup is exhibiting an entirely normal, expected finding ; buprenorphine requires a specific buprenorphine immunoassay. Conversely, a patient actively overdosing on illicit fentanyl will test "Negative for Opiates" on standard screens unless a dedicated fentanyl immunoassay is performed.

4. Metabolic Cascades: Differentiating Ingestion from Specimen Tampering

Definitive chromatography (LC-MS/MS) separates parent drugs from their in vivo hepatic metabolites. Understanding these metabolic pathways allows the APRN to confirm ingestion, detect illicit heroin, and identify specimen adulteration. Opioid Hepatic Metabolic Pathways:

  • Heroin (Diacetylmorphine)
  • │ (Half-life 3-5 min)
  • ▼
  • 6-Monoacetylmorphine (6-MAM) ──► [PATHOGNOMONIC FOR HEROIN USE!]
  • │ (Half-life 30-40 min, urine window 6-24 hours)
  • ▼
  • Morphine ◄── Codeine (10% via CYP2D6)
  • │
  • ▼ (Glucuronidation)
  • Morphine-3-glucuronide & Morphine-6-glucuronide
  • │ (Minor pathway)
  • ▼
  • Hydromorphone (trace)
  • Heroin vs. Prescription Opiate Identification

6-Monoacetylmorphine (6-MAM): Heroin is rapidly deacetylated in blood and tissues to 6-MAM, which is subsequently hydrolyzed to morphine. The presence of 6-MAM in urine is conclusive and pathognomonic for illicit heroin use . Because 6-MAM has a short half-life (urinary detection window only 6 to 24 hours), its absence does not exclude heroin; a sample showing high morphine without 6-MAM could represent remote heroin use, pharmaceutical morphine, or high-dose codeine.

Codeine Metabolism: Codeine is metabolized via hepatic CYP2D6 into morphine (approx. 10%) and via CYP3A4 into norcodeine. In a patient taking prescribed codeine, urine chromatography shows high concentrations of codeine accompanied by lower concentrations of morphine. If morphine concentration significantly exceeds codeine, or if codeine is absent, the patient ingested morphine or heroin, not codeine alone.

Buprenorphine Metabolism & The "Pill Spiking" Phenomenon

Sublingually administered buprenorphine undergoes extensive hepatic N-dealkylation primarily via CYP3A4 and glucuronidation (UGT1A1, UGT2B7) into its primary active metabolite, Norbuprenorphine . Buprenorphine Hepatic Metabolic Cascade:

  • [Prescribed Sublingual Buprenorphine]
  • │
  • ▼ (Hepatic In Vivo CYP3A4 Metabolism)
  • [Norbuprenorphine]
  • │
  • ▼ (Renal Excretion)
  • [Urine LC-MS/MS: BOTH Buprenorphine AND Norbuprenorphine Present]

LC-MS/MS Toxicological Finding Clinical Interpretation & Biochemical Mechanism

Buprenorphine (+) & Norbuprenorphine (+) Normal Adherence: The patient took the medication sublingually. Hepatic CYP3A4 metabolized the parent compound into norbuprenorphine in vivo. Norbuprenorphine levels frequently equal or exceed parent drug levels.

Buprenorphine (Very High >1,000–10,000 ng/mL) & Norbuprenorphine (NEGATIVE or <10 ng/mL) SPECIMEN TAMPERING ("PILL SPIKING"): The patient shaved, crushed, or dissolved a portion of their sublingual tablet or film directly into the urine collection cup! Because the drug never passed through a living human liver, no hepatic CYP3A4 metabolism occurred, resulting in massive parent drug concentration and zero norbuprenorphine.

Buprenorphine (-) & Norbuprenorphine (-) Non-Adherence / Diversion: The patient is not taking the medication, or the urine sample was substituted with synthetic urine or another individual's drug-free urine.

Buprenorphine (Trace/Low) & Norbuprenorphine (High) Delayed Collection / Normal Elimination: Indicates remote dosing (e.g., 24 to 48+ hours prior to sample collection), where the parent drug has largely cleared while the metabolite remains.

Methadone Metabolism & Tampering

Methadone is metabolized in the liver by CYP3A4, CYP2B6, and CYP2C19 into EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine) .

Adherent Ingestion: Urine contains both parent methadone and EDDP.

Spiked Cup: Massive methadone concentrations with undetectable EDDP indicates direct tampering (dropping liquid methadone into the collection cup).

5. Clinical Governance Matrix: Managing Discrepant UDT Results

Discrepant Finding Immediate Clinical Action Follow-Up Strategy

Unexpected Positive Immunoassay Do NOT accuse or penalize. Order definitive LC-MS/MS confirmation. Review medication list for cross-reacting agents (e.g., bupropion for amphetamines). Withhold punitive changes pending mass spectrometry confirmation. Discuss findings collaboratively.

Pill Spiking Confirmed (Parent (+) / Metabolite (-)) Explore barriers to adherence non-judgmentally: "The laboratory analysis shows that the medication was added directly to the cup without passing through your body. What challenges are you experiencing with taking your medication?" Evaluate for medication diversion, fear of withdrawal, or lost/stolen doses. Consider transitioning to observed dosing or long-acting injectable buprenorphine (Sublocade).

Unexpected Negative for Prescribed Drug Confirm whether an appropriate assay was utilized (e.g., dedicated buprenorphine or fentanyl assay vs. standard opiate screen). Check urine creatinine and specific gravity for specimen dilution. Assess for medication discontinuation, financial barriers, adverse side effects, or diversion. Re-establish therapeutic alliance.